Unicycive resubmits FDA NDA for oxylanthanum carbonate phosphate binder
Bitget2026/09/29 11:05- Unicycive resubmitted its FDA NDA for oxylanthanum carbonate to treat hyperphosphatemia in CKD patients on dialysis.
- Filing includes CMC data from a new manufacturing vendor, supporting FDA review with a new PDUFA date expected in six months.
- Prior CRLs in June 2025 and June 2026 cited third-party manufacturing deficiencies; FDA raised no clinical efficacy or safety issues.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic shares expected to open 26.5% above $83 IPO price
AMD shares drop over 8% after Hunterbrook announces short position in the company.

Federal Reserve Vice Chair Jefferson: The current AI boom is driving up inflation, but future productivity gains may lead to lower prices.
Federal Reserve Vice Chair Philip Jefferson stated that the AI boom could affect both demand and supply sides, though the timing of these impacts differs. On the demand side, corporate investments in data centers and advanced computing equipment are currently putting upward pressure on inflation. On the supply side, productivity improvements could exert downward pressure on prices, but this may only occur "in the future," and he did not provide a specific timeline.

BUZZ - Walmart shares fall as it forecasts annual sales below expectations